A tiny Tokyo-based diagnostics firm that developed the first U.S.-approved spinal fluid test for Alzheimer¡¯s is now doubling down on developing blood tests ¡ª an easier method to detect the brain-wasting disease against which a blockbuster therapy is expected soon.
Fujirebio Holding ¡ª a unit of H.U. Group Holdings, which has a market value of ?166.2 billion ($1.2 billion) ¡ª is boosting its lineup of reagents used to detect Alzheimer¡¯s biomarkers in blood tests. It aims to file these tests for approval in the United States as early as 2023, according to Fujirebio Chief Executive Officer Goki Ishikawa.
¡°The lineups offered by industry leaders are still limited,¡± Ishikawa said in an interview. ¡°We are rushing to create a solid lineup of tests as quickly as possible. We can¡¯t wait long, really have to start seeking approvals in the U.S. in a year or so.¡±
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.